Bone Sarcomas: From Biology to Targeted Therapies

Author:

Gaspar Nathalie1,Di Giannatale Angela1,Geoerger Birgit1,Redini Françoise2,Corradini Nadège3,Enz-Werle Natacha4,Tirode Franck5,Marec-Berard Perrine6,Gentet Jean-Claude7,Laurence Valérie8,Piperno-Neumann Sophie8,Oberlin Odile1,Brugieres Laurence1

Affiliation:

1. Department of Oncology for Children and Adolescents, Institut Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif Cedex, France

2. Inserm U957-EA 3822, Faculté de Médecine, 1 rue Gaston Veil, 44035 Nantes Cedex 1, France

3. Oncopediatric Departement, CHU de Nantes, Boulevard Jacques Monod, 44093 Nantes, France

4. Pediatric Onco-Hematology Department, EA 4438UdS, CHRU Strasbourg, Avenue Molière, 67000 Strasbourg, France

5. Unité 830 INSERM, Institut Curie, Centre de Recherche, 26 rue d’Ulm, 75248 Paris Cedex 05, France

6. Oncopediatric Departement, Centre Léon Bérard, 28 rue Laennec, 69008 Lyon, France

7. Oncopediatric Departement, Hôpital La Timone, 264 rue Saint Pierre, 13385 Marseille Cedex 5, France

8. Department of Medical Oncology, Institut Curie, 26 rue d’Ulm, 75248 Paris Cedex 05, France

Abstract

Primary malignant bone tumours, osteosarcomas, and Ewing sarcomas are rare diseases which occur mainly in adolescents and young adults. With the current therapies, some patients remain very difficult to treat, such as tumour with poor histological response to preoperative CT (or large initial tumour volume for Ewing sarcomas not operated), patients with multiple metastases at or those who relapsed. In order to develop new therapies against these rare tumours, we need to unveil the key driving factors and molecular abnormalities behind the malignant characteristics and to broaden our understanding of the phenomena sustaining the metastatic phenotype and treatment resistance in these tumours. In this paper, starting with the biology of these tumours, we will discuss potential therapeutic targets aimed at increasing local tumour control, limiting metastatic spread, and finally improving patient survival.

Publisher

Hindawi Limited

Subject

Radiology, Nuclear Medicine and imaging,Oncology

Cited by 23 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3